EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) to a sell rating in a report published on Saturday morning.

Other analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $30.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. Cantor Fitzgerald restated an overweight rating on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 20th. Chardan Capital restated a buy rating and issued a $28.00 target price on shares of EyePoint Pharmaceuticals in a research note on Friday, June 28th. JPMorgan Chase & Co. reduced their target price on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an overweight rating for the company in a research note on Tuesday, August 13th. Finally, Jefferies Financial Group assumed coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a buy rating and a $15.00 target price for the company. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals has an average rating of Moderate Buy and a consensus target price of $30.57.

EyePoint Pharmaceuticals Trading Up 0.6 %

Shares of EyePoint Pharmaceuticals stock opened at $8.34 on Friday. The business has a 50-day moving average price of $8.76 and a two-hundred day moving average price of $12.50. EyePoint Pharmaceuticals has a 1-year low of $5.67 and a 1-year high of $30.99. The company has a market cap of $434.38 million, a P/E ratio of -4.58 and a beta of 1.59.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $11.61 million. Equities research analysts forecast that EyePoint Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling at EyePoint Pharmaceuticals

In other EyePoint Pharmaceuticals news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $10.06, for a total transaction of $116,947.50. Following the completion of the transaction, the director now owns 1,850 shares in the company, valued at approximately $18,611. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Several hedge funds have recently modified their holdings of EYPT. Ameritas Investment Partners Inc. lifted its position in shares of EyePoint Pharmaceuticals by 44.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after buying an additional 1,136 shares in the last quarter. Greenwich Wealth Management LLC bought a new position in shares of EyePoint Pharmaceuticals during the 2nd quarter worth approximately $94,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of EyePoint Pharmaceuticals by 271.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after buying an additional 7,953 shares in the last quarter. Arizona State Retirement System lifted its position in shares of EyePoint Pharmaceuticals by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $115,000 after buying an additional 1,171 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 129.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,393 shares of the company’s stock worth $194,000 after buying an additional 5,308 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.